Navigation Links
NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
Date:9/26/2007

Company to develop for treatment of neurofibromatosis and cancer

NEW YORK, Sept. 26 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc., a privately held New York biotechnology company focused on developing drugs to treat the genetic disorder neurofibromatosis and related sporadic tumors, today announced that it has entered into a definitive agreement with Universite Louis Pasteur (ULP) and the Centre National de la Recherche Scientifique (CNRS) to in-license a novel family of Hsp90 inhibitors.

"Our preliminary evaluation of these compounds has yielded promising results in NF2 and cancer models", said Dr. Allan Rubenstein, CEO of NexGenix. "While targeting the inhibition of protein folding chaperones such as Hsp90 is an approach that is seeing success in clinical trials for cancer, this target has additionally been shown to be potentially promising for a number of therapeutic indications. We intend to evaluate this compound series for the treatment of several disorders."

Under the terms of this agreement, NexGenix will have an exclusive worldwide license to develop and commercialize the technology for human and animal therapeutic and diagnostic use from ULP and CNRS. NexGenix will be responsible for all development and commercialization costs and activities. In return, ULP and CNRS will be entitled to certain maintenance fees, milestone payments and royalties.

The company has additionally entered into a Collaborative Research Agreement with the Institut de Sciences et d'Ingenierie Supramoleculaires at ULP to further understanding of structure activity relationships and opportunities to improve the pharmacokinetic properties of the in-licensed Hsp90 inhibitor compound series. This research program is to be conducted at ULP by Nicolas Winssinger, PhD. Dr. Winssinger is one of the inventors of the compound series and is a member of the NexGenix Scientific Advisory Board.

About NexGenix Pharmaceuticals

NexGenix Pharmaceu
'/>"/>

SOURCE NexGenix Pharmaceuticals Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. WARF enters licensing agreements for stem cell products
4. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
5. Software company enters health space with RFID solutions on hold
6. Lucigen Corp. enters global licensing agreement
7. Call centers and customer service: The good, the bad, and the clueless
8. GE Healthcare enters agreement with Canadian health authority
9. Data centers: Buyers beware of over-hyped facilities
10. Data centers: Blowing smoke and raising red flags
11. Prodesse enters patent agreement with Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 The Pittcon Organizing Committee ... Food Safety Tech , an e-Journal and producer of ... agreement for the second year for the co-location of Food ... The partnership provides that the registration fee to attend the ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... Biotechnology Company, Limited ("TaiGen") today announced that they have ... pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ® ... Turkey and other members of ... for the treatment of bacterial infections including those caused ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Inc.,(OTC Bulletin Board: NGNM) announced today that it plans ... July 31, 2008., The Company has scheduled ... results on July 31, 2008, at 11:00 AM EDT. ... 689-8033 (international) at least,five minutes prior to the call. ...
... James C. Powell, former,President and Chief Operating Officer ... of Nerites Corporation., Under Powell,s guidance, SurModics ... partnerships to commercialize products.,Powell joined SurModics in 1987 ... lead the company,s transition from a diagnostics kit,manufacturer ...
... VEGAS, July 29 American Pacific,Corporation (Nasdaq: APFC ... third quarter financial results on Tuesday, August 5, 2008. ... to participate in,a teleconference to review the financial results ... held Tuesday, August 5, 2008 at 1:30 p.m.,PDT. To ...
Cached Biology Technology:NeoGenomics Schedules its Q2 2008 Earnings Release for July 31, 2008 2James C. Powell Joins Nerites Board of Directors 2American Pacific to Release Financial Results and Hold Fiscal 2008 Third Quarter Investor Teleconference 2
(Date:4/17/2014)... about eight years ago, Katia Silvera , a postdoctoral ... were on a field trip in a mountainous area in ... never seen before. , Unable to identify it, they contacted ... turned out to be an unnamed species. So Carnevali recently ... "Lophiaris" is the genus name, comprising about 40 species in ...
(Date:4/17/2014)... a novel method to help kidney stone sufferers ... treatment possible., Kidney stones represent a major medical ... left untreated, apart from being particularly painful, they ... In many patients treated successfully, stone recurrence is ... approach to diagnosis and treatment needs to be ...
(Date:4/17/2014)... expression is the process whereby the genetic information ... such as proteins, which have numerous different functions ... an important intermediary during gene expression, by relating ... mechanisms involved in manufacturing proteins. , By ... molecules present in an organism at a given ...
Breaking Biology News(10 mins):Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Rapid and accurate mRNA detection in plant tissues 2
... of £23.6M a year to the UK poultry industry but ... against the disease ?one that can be delivered while they ... vaccine virus which provides immunity to IBV has been developed ... vaccine company Intervet UK. It can be delivered to chicks ...
... simply grab carbon dioxide out of the air and covert ... plants use light as their energy source. Chemists would also ... source for their synthetic reactions, but it doesn’t work just ... Max Planck Institute for Colloids and Interfaces has now taken ...
... of Toronto is revealing biochemical processes responsible for diseases ... the way for pharmaceutical applications. , A study ... describes how U of T and Johns Hopkins University ... play an important role in human health and disease. ...
Cached Biology News:In-shell vaccine for chick disease 2Progress toward artificial photosynthesis? 2Technology reveals 'lock and key' proteins behind diseases 2
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Biology Products: